| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | <1 mi |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | Phase 1 | BioNTech SE | <1 mi |
| A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities | N/A | Johns Hopkins University | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| Dinner Time for Obesity and Prediabetes | N/A | Johns Hopkins University | <1 mi |
| A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM | Phase 3 | AstraZeneca | <1 mi |
| Integrating Free-choice Marketplace, dieTitian coacHing, cultuRally Tailored messagIng to improVE Blood Pressure | N/A | Johns Hopkins University | <1 mi |
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Improving Glycemic Control With Telemedicine and Smart Insulin Pens | N/A | University of Maryland, Baltimore | <1 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| Kidney Precision Medicine Project | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | <1 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics | — | Milton S. Hershey Medical Center | <1 mi |
| MiniMed Fit Payload Wear Pediatric Study | — | Medtronic MiniMed, Inc. | <1 mi |
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | Phase 2 | Jason Sperry | <1 mi |
| Taste Bud-Derived Stem Cells in Humans | — | National Institute on Aging (NIA) | <1 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms | — | Milton S. Hershey Medical Center | <1 mi |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | N/A | Endogenex, Inc. | <1 mi |
| GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | N/A | Medtronic MiniMed, Inc. | <1 mi |
| Imaging the Pathogenesis of Cerebral Small Vessel Disease | — | Johns Hopkins University | <1 mi |
| WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention | N/A | Johns Hopkins University | <1 mi |
| Night Owl Metabolism | N/A | Johns Hopkins University | <1 mi |
| Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration | N/A | Johns Hopkins University | <1 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | <1 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | <1 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | <1 mi |
| PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Phase 4 | Brigham and Women's Hospital | <1 mi |
| Rare and Atypical Diabetes Network | — | University of South Florida | <1 mi |
| Vasopressin and Pain Perception in the Brain | Phase 1/2 | University of Maryland, Baltimore | <1 mi |
| A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | Phase 3 | Vertex Pharmaceuticals Incorporated | <1 mi |
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Phase 2 | Pharming Technologies B.V. | <1 mi |
| ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2 | N/A | Johns Hopkins University | <1 mi |
| Bionic Pancreas in CFRD | Phase 3 | Jaeb Center for Health Research | <1 mi |
| The Effects of Fluoxetine and/or DHEA | Early 1 | University of Maryland, Baltimore | <1 mi |
| Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease | N/A | Johns Hopkins University | <1 mi |
| Groceries Plus Multi-Component Lifestyle Intervention for Adults With Hypertension and Type 2 Diabetes | N/A | Johns Hopkins University | <1 mi |
| Nutrition Optimization and Community Upliftment for Postpartum Recovery | N/A | Johns Hopkins University | <1 mi |
| Glucose Variability and Cognition in Prediabetes | — | University of Maryland, Baltimore | <1 mi |
| Understanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure | N/A | Johns Hopkins University | <1 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | <1 mi |
| A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | Phase 3 | Pfizer | 9 mi |
| A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | 10 mi |
| Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management | N/A | Legacy Medical Consultants | 12 mi |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Hoffmann-La Roche | 13 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | 13 mi |
| Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes | Phase 3 | Kailera | 13 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 13 mi |
| Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Phase 3 | Kailera | 13 mi |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | 13 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | 25 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | 26 mi |
| A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | Phase 2 | Corxel Pharmaceuticals | 30 mi |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | 30 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | 32 mi |
| A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | 32 mi |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Phase 3 | Novo Nordisk A/S | 32 mi |
| Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| Genetic Studies of Insulin and Diabetes | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| A Natural History Study of Metabolic Sizing in Health and Disease | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| Caregiving Networks Across Disease Context and the Life Course | — | National Human Genome Research Institute (NHGRI) | 34 mi |
| A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Phase 1 | GigaGen, Inc. | 34 mi |
| The LD Lync Study - Natural History Study of Lipodystrophy Syndromes | — | University of Michigan | 34 mi |
| National Eye Institute Biorepository for Retinal Diseases | — | National Eye Institute (NEI) | 34 mi |
| Urinary Vitamin C Loss in Diabetic Subjects | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| New Heart Imaging Techniques to Evaluate Possible Heart Disease | N/A | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| Diabetes and Heart Disease Risk in Blacks | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| Diabetes Reversal Online Program and Study (DROP Study) | N/A | Physicians Committee for Responsible Medicine | 36 mi |
| RESET System Pivotal Trial (Rev F) | N/A | Morphic Medical Inc. | 36 mi |
| Family Intervention for Black Teens With Type 1 Diabetes | N/A | Wayne State University | 36 mi |
| Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes | N/A | George Washington University | 36 mi |
| The CARING Study: Creating and Restoring Health Through Nutrition Guidance | N/A | Physicians Committee for Responsible Medicine | 36 mi |
| Texts for Diabetes Control Among Homeless Persons | N/A | George Washington University | 36 mi |
| A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | Phase 1/2 | Alnylam Pharmaceuticals | 36 mi |
| Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes | Phase 2 | George Washington University | 36 mi |
| North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | — | Columbia University | 36 mi |
| Pragmatic Clinic-Based Trial of a Mindfulness Based Intervention for Mood Concerns in Youth With Type 1 Diabetes | N/A | Children's National Research Institute | 36 mi |
| A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | — | AstraZeneca | 37 mi |
| Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial | N/A | Sonavex, Inc. | 39 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin | Phase 3 | AstraZeneca | 39 mi |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | Phase 3 | NewAmsterdam Pharma | 39 mi |
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Phase 2 | Novo Nordisk A/S | 39 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Phase 2/3 | CSL Behring | 48 mi |
| HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes | Phase 2 | Housey Healthcare ULC | 49 mi |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy | Phase 2 | Biomea Fusion Inc. | 49 mi |